MedTrace Logo

Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

NCT00684853 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-05-28

No results posted yet for this study

Summary

The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD

Conditions

  • Macular Degeneration

Interventions

DRUG

bevacizumab

1.25 mg of bevacizumab intravitreal

DRUG

vetaporfin

full fluence of vetaporfin

Sponsors & Collaborators

  • Federal University of São Paulo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684853 on ClinicalTrials.gov